Summary of patient outcomes
| Sarilumab (n=28) | Comparison group (n=28) | P value | |
| Clinical improvement, n (%) | 17 (60) | 18 (64) | 0.99 |
| Time to clinical improvement (days) | 18 (9–28) | 19 (11–28) | 0.89 |
| Death, n (%) | 2 (7) | 5 (18) | 0.42 |
| Time to death (days) | 19 (13–26) | 4 (3–4) | 0.006 |
| Live discharge, n (%) | 17 (60) | 17 (60) | 0.99 |
| Time to discharge (days) | 12 (8–20) | 13 (10–20) | 0.35 |
| Mechanical ventilation, n (%) | 6 (21) | 7 (25) | 0.99 |
| Time to mechanical ventilation (days) | 5 (1–6) | 3 (2–4) | 0.52 |
| Fever resolution, n (%) | 28 (100) | 28 (100) | 0.99 |
| Time to fever resolution (days) | 1 (1–1) | 4 (1–4) | <0.0001 |
| CRP normalisation, n (%) | 24 (86) | 17 (61) | 0.06 |
| Time to CRP normalisation (days) | 6 (4–7) | 12 (9–15) | <0.0001 |
| Adverse events | |||
| Infections | 6 (21) | 5 (18) | 0.99 |
| Neutropenia | 4 (14) | 0 (0) | 0.11 |
| Increase in liver enzymes | 4 (14) | 0 (0) | 0.11 |
| Thromboembolism | 2 (7) | 2 (7) | 0.99 |
Categorical data are reported as number of patients (n) and percentage (%). Increase in liver enzymes indicates an increase in serum levels of alanine aminotransferase and aspartate aminotransferase more than three times the upper limit of normal. A p value < 0.05 was considered statistically significant.
Bold indicates significant values.
CRP, C-reactive protein.